Adverum Biotechnologies to Participate in the Jefferies Healthcare Conference
02 Junio 2023 - 7:00AM
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage
company that aims to establish gene therapy as a new standard of
care for highly prevalent ocular diseases, today announced that
Laurent Fischer, M.D., president and chief executive officer will
present at the Jefferies Healthcare Conference on Friday, June 9,
2023 at 10:00 a.m. ET in New York, New York.
The on-demand webcast fireside may be accessed under Events
and Presentations in the Investors section of Adverum’s
website. A replay of the webcast will be available on the website
for 90 days following the presentation.
About Adverum Biotechnologies
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage
company that aims to establish gene therapy as a new standard of
care for highly prevalent ocular diseases with the aspiration of
developing functional cures to restore vision and prevent
blindness. Leveraging the capabilities of its proprietary
intravitreal (IVT) platform, Adverum is developing durable,
single-administration therapies, designed to be delivered in
physicians’ offices, to eliminate the need for frequent ocular
injections to treat these diseases. Adverum is evaluating its novel
gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly
referred to as ADVM-022), as a one-time, IVT injection for patients
with neovascular or wet age-related macular degeneration. By
overcoming the challenges associated with current treatment
paradigms for debilitating ocular diseases, Adverum aspires to
transform the standard of care, preserve vision, and create a
profound societal impact around the globe. For more information,
please visit www.adverum.com.
Corporate, Investor and Media Inquiries
Anand ReddiVice President, Head of Corporate Strategy, External
Affairs and EngagementAdverum Biotechnologies, Inc.T:
650-649-1358E: areddi@adverum.com
Adverum Biotechnologies (NASDAQ:ADVM)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Adverum Biotechnologies (NASDAQ:ADVM)
Gráfica de Acción Histórica
De May 2023 a May 2024